Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Short-Term Debt issuances (2024 - 2025)

Cytek Biosciences (CTKB) has disclosed Short-Term Debt issuances for 2 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-Term Debt issuances fell 49.43% year-over-year to $1.4 million, compared with a TTM value of $5.6 million through Dec 2025, up 33.25%, and an annual FY2025 reading of $5.6 million, up 33.51% over the prior year.
  • Short-Term Debt issuances was $1.4 million for Q4 2025 at Cytek Biosciences, down from $2.1 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $2.8 million in Q4 2024 and bottomed at -$3000.0 in Q2 2024.